Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057454 · ClinicalTrials.gov registry record · Phase 1
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
A Phase 1 study, sponsored by Rise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT06057454 is a Phase 1 study that has completed, run by Rise Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT06057454, a Phase 1 study, has completed, sponsored by Rise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Interventions
- OTHER Placebo
- DRUG R-5280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2025-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06057454
The ClinicalTrials.gov registry entry for NCT06057454 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rise Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06057454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06057454 about?
NCT06057454 is a clinical study titled "R-5280 in Newly Diagnosed Patients With Type 1 Diabetes". Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
What is the current status of trial NCT06057454?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-12-05. Estimated completion is 2025-11-05.
What interventions are being tested in trial NCT06057454?
The interventions under investigation include: Placebo (OTHER), R-5280 (DRUG).
Who is sponsoring clinical trial NCT06057454?
This trial is sponsored by Rise Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.